Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Working Life
Time for in-house pharma marketers to stay put
People working in marketing departments of Australian pharmaceutical and healthcare companies are being advised to sit tight for the next 12 months as companies batten down the hatches and settle in after a period of strong growth.
Approvals Action
Sanofi registers once daily insulin
As generic competition looms for big seller Lantus, Sanofi has registered a once-daily, long-acting version of the diabetes treatment under the brands Toujeo, Lambeto and Edomlus.
PBS Top Five
Mental health: Generics vs brands
A number of the most lucrative drugs are hanging onto exclusivity by a thread, or relying on extended release formulations to beat generic copies, while many genericised drugs are still commanding some of the highest earnings in the mental health category.
Open Forum
Pharma supply chain challenges abound
Saul Resnick, Managing Director, DHL Supply Chain Australia, looks at how pharma can be smarter about their use of supply chains.
Pipeline Monitor
Anticoagulant and blood thinner approved
Approval for anticoagulant, blood thinner while new class of cancer medicine, enzyme replacement therapies and a swag of others bag recommendations.
christian louboutin heels yves saint laurent bags replica hermes replica belt prada wallet outlet celine luggage tote replica prada shoes hermes handbags sale hermes outlet bag hermes kelly bag outlet hermes replica hermes belt outlet red bottoms men hermes bag birkin chloe handbags for cheap 2015 celine phantom bag sale hermes outlet